Patheon Inc. (TSX: PTI) today announced that
Patheon has entered into a five-year master supply agreement with Merck & Co.,
Inc. (NYSE: MRK) to provide commercial manufacturing and pharmaceutical
development services to Merck, and that Merck has selected Patheon as one of
Merck's strategic partners for commercial manufacturing and pharmaceutical
development services.
